Research & Development
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
19 August 2026 - Aqua Medical Inc, a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration, announced on Tuesday the treatment of the first West Coast patient (second ov...
Harbour BioMed IND for HBM7004 approved by China's NMPA
18 August 2026 - Global biopharmaceutical company Harbour BioMed (HKEX: 02142), which develops antibody therapeutics in immunology and oncology, said on Tuesday that China's National Medical Prod...
Hansa Biopharma reports first Australian transplant using Idefirix
18 August 2026 - Swedish immunomodulatory therapy company Hansa Biopharma AB (STO: HNSA) on Tuesday announced that the first commercial patient in Australia has received a living donor kidney transpla...
Lupin's Pitolisant Tablets receives US FDA approval
18 August 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257; NSE: LUPIN; REUTERS: LUPIN.BO; BLOOMBERG: LPCIN) announced on Monday that it has received the final approval from...
Acurx receives FDA conditional acceptance for ibezapolstat brand name
17 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) disclosed on Monday that it has received conditional FDA acceptance for CIFBEZY, the proposed proprietary name for i...
Lttl announces new telehealth site
17 August 2026 - US-based, direct-to-consumer telehealth brand Lttl reported on Friday that it has launched a new site that specialises in personalised GLP-1 weight management, longevity protocols, an...